Saint Barnabas Health Care System Oncology Services - Cancer Programs and Services at Saint Barnabas Medical Center: Patient Care Services

Research/Clinical Trials

Our medical staff is committed to offering the most up-to-date treatments available. Most of these will be available at Saint Barnabas Medical Center, although there may be times we recommend that you consider a very specialized treatment which may be available only at another center. In addition, to broaden your treatment options, we will inform you of any clinical trials for which you may be eligible. Our Center is involved in many clinical trials run both by the National Cancer Institute and by individual pharmaceutical companies. Today's clinical trials lead to tomorrow's breakthrough treatments.

For more information on clinical trials, please contact our Research Manager at (973) 322-2470.

Breast Cancer Trials Stage I, II, III
Breast Cancer Trials Metastatic
Endometrial Cancer State III and IV
GastroIntestinal STAGE I, II, III
GastroIntestinal Metastatic
Genitourinary
Glioblastoma
Lung Metastatic
Melanoma
Multiple Myeloma
Myeloma
Ovarian
Prostate

Breast Cancer Trials Stage I, II, III

E5103	A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
NSABP B-39	A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
CTSU PACCT-1Tailor	Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
CTSU S0307	Phase III Trial of Bisphosphonates ( Zoledronic acid Vs. Clodronate Vs. Ibandronate) as Adjuvant Therapy for Primary Breast Cancer.
SWOG S0221	Phase III trial of Continuous schedule AC+GCSF Vs every 2 week schedule AC, followed by Paclitaxel given either Every 2 weeks or weekly for 12 weeks as Post operative adjuvant therapy in node positive or high risk node negative breast.
CTSU MA.27	A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer. (Includes Two Sub-studies)
CTSU IBSCG24-02 SOFT	A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT)
NSABP B-42	A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

Breast Cancer Trials Metastatic
CZOL446E2352	A prospective, randomized, stratified, placebo-controlled, multi-center, 2-arm trial of the continued efficacy and safety of Zometa (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from breast cancer.
CA023	A Randomized Phase II Trial of Weekly vs. Every 2-Week versus Every 3-week Administration of Abraxane in combination with Bevacizumab (Avastin) in Women with untreated Metastatic Breast Cancer
AVF4057g	A multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy And Safety of Sunitinib in Combination with BEVACIZUMAB (Avastin) And PACLITAXEL In Previously Untreated Patients With Metastatic Breast Cancer
TOC4129g	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer
EZ-EPO307975	Phase 2 study to investigate the efficacy and safety of ZK-Epothilone (ZK-Epo; ZK 219477) in patients with metastatic breast cancer
TDM4258g	Phase II, single-Arm, Open label, Study of trastuzumab-MCC-DM1 administered intravenously to patients with Her2-Positive metastatic breast cancer that have progressed while receiving Her2 positive directed therapy.
CALGB 40302	Endocrine Therapy With or Without Inhibition of EGF & HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatanib for Postmenopausal Women with ER &/or PR Positive Advanced Breast Cancer
Endometrial Cancer state III and IV
GOG0209	Randomized Phase III Trial of DOXORUBICIN/CISPLATIN/PACLITAXEL And G-CSF Versus CARBOPLATIN/PACLITAXEL In Patients With Stage III & IV Or Recurrent Endometrial Cancer
GastroIntestinal STAGE I, II, III
CALGB80101	Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma
CTSU E5202	A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
CTSU N0147	A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
CTSU E2204	An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely-Resected Pancreatic Carcinoma
RAD001-CRAD001C2324	A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET)
GastroIntestinal Metastatic
NSABP C-10	A Phase II Trial of mFOLFOX6 Chemotherapy Plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor
CALGB80405	A Phase III Trial Of Irinotecan/5-FU/Leucovorin Or Oxaliplatin/5-FU/Leucovorin With Bevacizumab, Or Cetuximab(C225), Or With The Combination Of Bevacizumab & Cetuximab For Patients With Untreated Mets Adenocarcinoma Of The Colon Or Rectum
S0600	Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on (1st line) Bevacizumab with either FOLFOX, OPTIMOX or XELOX
Genitourinary
CTSU E2805	A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients with Resected Renal Cell Carcinoma
Glioblastoma
RTOG0525	A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients Treated for Favorable-Risk Prostate Cancer
Lung Metastatic
AVF3671g	A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Avastin Therapy With OR Without ERLOTINIB After Completion Of Chemotherapy With BEVACIZUMAB For The First-Line Treatment Of Locally Advanced Or Metastatic Non-Squamous Non–Small Cell Lung Cancer
Melanoma
CTSU E2603	A Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma
Multiple Myeloma
C09005	Randomized Ph3 study of 3 Novel treatment regimens in subjects with previously untreated multiple myeloma who are not considered candidates for high dose chemotherapy and autologous stem cell transplantation: Velcade (Bortezomib), Thalomid (Thalidomide), and Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD) vs. Velcade, Melphalan, and Prednisone (VMP)
Ovarian
CTSU GOG0218	A Phase III Trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab followed by placebo,VS. Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer
Prostate
RTOG0232	A Phase III Study Comparing Combined External Beam Radiation AND Transperineal Intestitial Permanent Brachytherapy With Brachytherapy Alone For Selected Patients With Intermediate Risk Prostatic Carcinoma
RTOG0415	A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients Treated for Favorable-Risk Prostate Cancer
CALGB9594	INTERMITTENT ANDROGEN DEPRIVATION IN PATIENTS WITH STAGE D2 PROSTATE CANCER PHASE III
TPI-287	A Phase II Trial of TPI 287 in patients with metastatic Prostate Cancer Who have progressive Neoplastic Disease following treatment with one prior Taxane Regimen

[ top ] [ Back to Patient Care Services ]

�	About The Cancer Center of Saint Barnabas/Contact Us
•	Meet Our Medical Oncologists
�	Patient Care Services
•	Patient Resources and Events
�	Directions

Cancer Center at Clara Maass Med Ctr | Cancer Center at Monmouth Med Ctr
Cancer Center at Saint Barnabas Med Ctr
Cancer Center at Newark Beth Israel | Oncology Services at Community Medical Ctr
Kimball Regional Cancer Center | Programs and Services at Saint Barnabas Ambulatory Care Ctr

Saint Barnabas Health Care System
95 Old Short Hills Road
West Orange, New Jersey 07039
(888) SBHS-123 or (888) 724-7123